A team of researchers affiliated with several entities in Thailand, working with two colleagues from the US and two from Canada, has developed an mRNA COVID-19 vaccine that can be safely refrigerated for up to three months before use. The team has named it ChulaCov19. In their paper published in the journal Nature Microbiology, the group describes the differences between their vaccine and other mRNA COVID-19 vaccines. Amid the global pandemic, groups around the world have developed vaccines to protect or lessen symptoms of people from/with COVID-19. And of the 172 vaccines developed to date, 40 are RNA-based.
Lalita Panicker is consulting editor, views, Hindustan Times, New Delhi